Ornidazole Manufacturing Plant Project Report

Ornidazole Manufacturing Plant Project Report (DPR) Summary:

IMARC Group's comprehensive DPR report, titled "Ornidazole Manufacturing Plant Project Report 2026: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue," provides a complete roadmap for setting up an ornidazole manufacturing unit. The ornidazole market is driven by the increasing availability of generic formulations, which is improving affordability and broadening patient access, particularly in price-sensitive markets. According to IMARC Group, Asia Pacific accounts for approximately 42.0% of the global market.

This feasibility report covers a comprehensive market overview to micro-level information such as unit operations involved, raw material requirements, utility requirements, infrastructure requirements, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, etc.

The ornidazole manufacturing plant setup cost is provided in detail covering project economics, capital investments (CapEx), project funding, operating expenses (OpEx), income and expenditure projections, fixed costs vs. variable costs, direct and indirect costs, expected ROI and net present value (NPV), profit and loss account, financial analysis, etc.

Access the Detailed Feasibility Analysis, Request Sample

What is Ornidazole?

Ornidazole is a potent synthetic nitroimidazole antibiotic and antiprotozoal medication widely used to treat diverse bacterial and parasitic infections. The drug operates by entering microbial cells via passive diffusion, where it undergoes reductive activation to form toxic metabolites. These active products directly bind to and disrupt microbial DNA chains, halting vital protein synthesis and causing cell death. Ornidazole is highly effective against anaerobic bacteria and specific parasites, making it a primary treatment choice for conditions like amoebiasis, giardiasis, trichomoniasis, and bacterial vaginosis.

Key Investment Highlights

• Process Used: Nucleophilic substitution, epoxide ring-opening, condensation, purification and crystallization.
• End-use Industries: Pharmaceutical, healthcare, hospitals, clinics, veterinary and research institutions.
• Applications: Used as an antimicrobial and antiprotozoal agent for the treatment of anaerobic bacterial infections and protozoal infections.

Ornidazole Plant Capacity:

The proposed facility is designed with an annual production capacity ranging between 200–800 MT, enabling economies of scale while maintaining operational flexibility.

Ornidazole Plant Profit Margins:

The project demonstrates healthy profitability potential under normal operating conditions. Gross profit margins typically range between 30–40%, supported by stable demand and value-added applications.

• Gross Profit: 30–40%
• Net Profit: 14-20%

Ornidazole Plant Cost Analysis:

The operating cost structure of an ornidazole manufacturing plant is primarily driven by raw material consumption, including 2-Methyl-5-nitroimidazole and optically active epoxy chloropropane, which accounts for approximately 60–75% of total operating expenses (OpEx).

• Raw Materials: 60–75% of OpEx
• Utilities: 10-15% of OpEx

Financial Projection:

The financial projections for the proposed project have been developed based on realistic assumptions related to capital investment, operating costs, manufacturing capacity utilization, pricing trends, and demand outlook. These projections provide a comprehensive view of the project’s financial viability, ROI, profitability, and long-term sustainability.

Major Applications:

• Pharmaceuticals (antiprotozoal and antibacterial medications for the treatment of susceptible infections)
• Hospitals & Clinics (treatment of anaerobic bacterial and protozoal infections)
• Gynecology (management of certain gynecological infections caused by susceptible microorganisms)
• Gastroenterology (treatment of intestinal and gastrointestinal protozoal infections)

Why Ornidazole Manufacturing?

✓ Essential Pharmaceutical Ingredient: Ornidazole is an important antimicrobial and antiprotozoal drug used in the treatment of infections caused by anaerobic bacteria and protozoan parasites, supporting continued demand across pharmaceutical formulations and healthcare applications.

✓ Moderate but Justifiable Entry Barriers: Ornidazole manufacturing requires controlled chemical synthesis, precise reaction conditions, stringent impurity management and compliance with pharmaceutical quality standards. Regulatory approvals, validated manufacturing processes and consistent product quality create entry barriers favouring experienced producers.

✓ Healthcare Demand Alignment: The continued burden of anaerobic bacterial and protozoal infections, along with ongoing demand for effective anti-infective therapies, supports the need for ornidazole as an active pharmaceutical ingredient (API) and finished pharmaceutical formulations.

✓ Pharmaceutical Manufacturing & Regulatory Push: Expansion of pharmaceutical manufacturing, increasing investments in domestic API production, and government initiatives supporting local drug manufacturing and supply-chain resilience create opportunities for ornidazole producers. Quality systems and regulatory compliance remain important for accessing domestic and export markets.

✓ Localization and Dependability in Supply Chains: Pharmaceutical manufacturers increasingly require reliable and consistent API supplies to maintain uninterrupted formulation production. Local ornidazole manufacturing can help reduce dependence on imports, improve supply reliability, shorten procurement lead times and support regional pharmaceutical supply chains.

Transforming Vision into Reality:

This report provides the comprehensive blueprint needed to transform your ornidazole manufacturing vision into a technologically advanced and highly profitable reality.

Ornidazole Industry Outlook 2026:

The ornidazole industry is expected to witness steady growth, supported by the increasing prevalence of bacterial and protozoal infections and the continued demand for effective antimicrobial therapies. Ornidazole is widely utilized in the treatment of amoebiasis, giardiasis, trichomoniasis, and infections caused by anaerobic bacteria, supporting its demand across hospitals, clinics, and retail pharmacies. The growing healthcare burden in developing economies, improving access to diagnostic and treatment services, and expanding pharmaceutical manufacturing capabilities are strengthening market prospects. Pharmaceutical companies are also focusing on improving manufacturing efficiency, product quality, and distribution networks to strengthen their competitive presence. The Indian pharmaceutical market is a case in point; IBEF indicates that the market is slated to grow 7-9% in FY26 fueled by robust domestic demand, new product innovation and expansion into Europe. Looking ahead, rising healthcare expenditure, expanding generic drug production, and growing awareness of infectious disease management are expected to support the ornidazole industry's long-term outlook.

Leading Ornidazole Manufacturers:

Leading manufacturers in the global ornidazole industry include several multinational companies with extensive manufacturing capacities and diverse application portfolios. Key players include:

• Suyash Laboratories
• Endoc Pharma
• Lasa Loboratory
• Supor Group
• Nanjing Sanhome

all of which serve end-use sectors such as pharmaceutical, healthcare, hospitals, clinics, veterinary and research institutions.

How to Setup a Ornidazole Manufacturing Plant?

Setting up an ornidazole manufacturing plant requires evaluating several key factors, including technological requirements and quality assurance. Some of the critical considerations include:

• Detailed Process Flow: The manufacturing process is a multi-step operation that involves several unit operations, material handling, and quality checks. Below are the main stages involved in the ornidazole manufacturing process flow:
  • Unit Operations Involved
  • Mass Balance and Raw Material Requirements
  • Quality Assurance Criteria
  • Technical Tests
     
• Site Selection: The location must offer easy access to key raw materials such as 2-Methyl-5-nitroimidazole and optically active epoxy chloropropane. Proximity to target markets will help minimize distribution costs. The site must have robust infrastructure, including reliable transportation, utilities, and waste management systems. Compliance with local zoning laws and environmental regulations must also be ensured.​
   
• Plant Layout Optimization: The layout should be optimized to enhance workflow efficiency, safety, and minimize material handling. Separate areas for raw material storage, manufacturing, quality control, and finished goods storage must be designated. Space for future expansion should be incorporated to accommodate business growth.​
   
• Equipment Selection: High-quality, corrosion-resistant machinery tailored for ornidazole manufacturing must be selected. Essential equipment includes reaction vessels, stirred-tank reactors, controlled-temperature systems, dosing and addition systems, condensers, filtration units, solvent recovery systems, crystallizers, centrifuges, vacuum dryers, milling units, and pharmaceutical-grade packaging machines. All machinery must comply with industry standards for safety, efficiency, and reliability.​
   
• Raw Material Sourcing: Reliable suppliers must be secured for raw materials like 2-Methyl-5-nitroimidazole and optically active epoxy chloropropane to ensure consistent manufacturing quality. Minimizing transportation costs by selecting nearby suppliers is essential. Sustainability and supply chain risks must be assessed, and long-term contracts should be negotiated to stabilize pricing and ensure a steady supply.
   
• Safety and Environmental Compliance: Safety protocols must be implemented throughout the manufacturing process of ornidazole. Advanced monitoring systems should be installed to detect leaks or deviations in the process. Effluent treatment systems are necessary to minimize environmental impact and ensure compliance with emission standards.​
   
• Quality Assurance Systems: A comprehensive quality management system should be implemented across all stages of operations to ensure consistent product and service standards. Appropriate testing, monitoring, and validation processes must be established to evaluate performance, safety, reliability, and compliance with applicable regulatory and industry requirements. Standard operating procedures (SOPs), documentation protocols, and traceability mechanisms should be maintained to support transparency, risk management, and continuous improvement. Regular audits, inspections, and corrective action frameworks should also be integrated to enhance overall operational excellence.

Project Economics:

​Establishing and operating an ornidazole manufacturing plant involves various cost components, including:​

• Capital Investment: The total capital investment depends on plant capacity, technology, and location. This investment covers land acquisition, site preparation, and necessary infrastructure.
   
• Equipment Costs: Equipment costs, such as those for reaction vessels, stirred-tank reactors, controlled-temperature systems, dosing and addition systems, condensers, filtration units, solvent recovery systems, crystallizers, centrifuges, vacuum dryers, milling units, and pharmaceutical-grade packaging machines, represent a significant portion of capital expenditure. The scale of manufacturing and automation level will determine the total cost of machinery.​
   
• Raw Material Expenses: Raw materials, including 2-Methyl-5-nitroimidazole and optically active epoxy chloropropane, are a major part of operating costs. Long-term contracts with reliable suppliers will help mitigate price volatility and ensure a consistent supply of materials.​
   
• Infrastructure and Utilities: Costs associated with land acquisition, construction, and utilities (electricity, water, steam) must be considered in the financial plan.
   
• Operational Costs: Ongoing expenses for labor, maintenance, quality control, and environmental compliance must be accounted for. Optimizing processes and providing staff training can help control these operational costs.​
   
• Financial Planning: A detailed financial analysis, including income projections, expenditures, and break-even points, must be conducted. This analysis aids in securing funding and formulating a clear financial strategy. 

Capital Expenditure (CapEx) and Operational Expenditure (OpEx) Analysis:

Capital Investment (CapEx): Machinery costs account for the largest portion of the total capital expenditure. The cost of land and site development, including charges for land registration, boundary development, and other related expenses, forms a substantial part of the overall investment. This allocation ensures a solid foundation for safe and efficient plant operations.

Operating Expenditure (OpEx): In the first year of operations, the operating cost for the ornidazole manufacturing plant is projected to be significant, covering raw materials, utilities, depreciation, taxes, packing, transportation, and repairs and maintenance. By the fifth year, the total operational cost is expected to increase substantially due to factors such as inflation, market fluctuations, and potential rises in the cost of key materials. Additional factors, including supply chain disruptions, rising consumer demand, and shifts in the global economy, are expected to contribute to this increase.

Capital Expenditure Breakdown:

To access CapEx Details, Request Sample

Operational Expenditure Breakdown:

To access OpEx Details, Request Sample

Profitability Analysis:

To access Financial Analysis, Request Sample

Latest Industry Developments:

• September 2025: A research study published in International Journal of Pharmaceutical Sciences developed and characterized an Ornidazole nanosuspension to enhance solubility, dissolution, and patient compliance. The optimized Ornidazole nanosuspension (F7) offered promising potential as a patient-friendly oral dosage form for paediatric and adult populations, combining enhanced therapeutic efficiency with improved stability.

Report Coverage:

Key Questions Answered in This Report?

• How has the Ornidazole market performed so far and how will it perform in the coming years?
• What is the market segmentation of the global Ornidazole market?
• What is the regional breakup of the global Ornidazole market?
• What are the price trends of various feedstocks in the Ornidazole industry?
• What is the structure of the Ornidazole industry and who are the key players?
• What are the various unit operations involved in an ornidazole manufacturing plant?
• What is the total size of land required for setting up an ornidazole manufacturing plant?
• What is the layout of an ornidazole manufacturing plant?
• What are the machinery requirements for setting up an ornidazole manufacturing plant?
• What are the raw material requirements for setting up an ornidazole manufacturing plant?
• What are the packaging requirements for setting up an ornidazole manufacturing plant?
• What are the transportation requirements for setting up an ornidazole manufacturing plant?
• What are the utility requirements for setting up an ornidazole manufacturing plant?
• What are the human resource requirements for setting up an ornidazole manufacturing plant?
• What are the infrastructure costs for setting up an ornidazole manufacturing plant?
• What are the capital costs for setting up an ornidazole manufacturing plant?
• What are the operating costs for setting up an ornidazole manufacturing plant?
• What should be the pricing mechanism of the final product?
• What will be the income and expenditures for an ornidazole manufacturing plant?
• What is the time required to break even?
• What are the profit projections for setting up an ornidazole manufacturing plant?
• What are the key success and risk factors in the Ornidazole industry?
• What are the key regulatory procedures and requirements for setting up an ornidazole manufacturing plant?
• What are the key certifications required for setting up an ornidazole manufacturing plant?

Report Customization

While we have aimed to create an all-encompassing report, we acknowledge that individual stakeholders may have unique demands. Thus, we offer customized report options that cater to your specific requirements. Our consultants are available to discuss your business requirements, and we can tailor the report's scope accordingly. Some of the common customizations that we are frequently requested to make by our clients include:

• The report can be customized based on the location (country/region) of your plant.
• The plant’s capacity can be customized based on your requirements.
• Plant machinery and costs can be customized based on your requirements.
• Any additions to the current scope can also be provided based on your requirements.

Why Buy IMARC Reports?

• The insights provided in our reports enable stakeholders to make informed business decisions by assessing the feasibility of a business venture.
• Our extensive network of consultants, raw material suppliers, machinery suppliers and subject matter experts spans over 100+ countries across North America, Europe, Asia Pacific, South America, Africa, and the Middle East.
• Our cost modeling team can assist you in understanding the most complex materials. With domain experts across numerous categories, we can assist you in determining how sensitive each component of the cost model is and how it can affect the final cost and prices.
• We keep a constant track of land costs, construction costs, utility costs, and labor costs across 100+ countries and update them regularly.
• Our client base consists of over 3000 organizations, including prominent corporations, governments, and institutions, who rely on us as their trusted business partners. Our clientele varies from small and start-up businesses to Fortune 500 companies.
• Our strong in-house team of engineers, statisticians, modeling experts, chartered accountants, architects, etc. have played a crucial role in constructing, expanding, and optimizing sustainable manufacturing plants worldwide.